ADReCS

Pharmaceutical Information

Drug Name	Oxcarbazepine
Drug ID	BADD_D01637
Description	Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L863] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine].[A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.[A186032]
Indications and Usage	In the United States, oxcarbazepine is indicated as monotherapy in the treatment of partial-onset seizures in patients 4 years of age and older, and as adjunctive therapy in the treatment of partial-onset seizures in patients 2 years of age and older.[L8627] In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]
Marketing Status	approved
ATC Code	N03AF02
DrugBank ID	DB00776
KEGG ID	D00533
MeSH ID	D000078330
PubChem ID	34312
TTD Drug ID	D0QL3P
NDC Product Code	72888-089; 55512-0023; 0078-0457; 50268-649; 51672-4106; 65162-649; 68071-2973; 70518-3197; 71428-007; 72888-088; 48087-0114; 55512-0008; 55512-0018; 72761-033; 76047-001; 31722-024; 50383-312; 60429-062; 62756-183; 71335-0090; 58159-088; 65372-1104; 17772-122; 50268-679; 60429-061; 63629-6834; 68462-139; 69452-125; 0615-8292; 60687-733; 63629-3816; 68084-845; 68462-138; 68788-7866; 70518-2370; 70518-3237; 72189-339; 0615-8448; 72888-074; 0904-7263; 42419-029; 48087-0157; 66406-0244; 66406-0246; 69766-055; 51672-4105; 51672-4107; 55154-8187; 62756-184; 68084-867; 70518-2276; 70518-3127; 71335-0505; 0615-8153; 48087-0115; 62512-0058; 70966-0004; 0078-0456; 17772-123; 50268-681; 68084-853; 70518-1027; 70518-1842; 70518-2254; 42419-006; 51508-008; 31722-025; 60687-711; 63629-9186; 70518-0894; 70518-2377; 0615-8447; 55512-0017; 82334-001; 0078-0357; 31722-023; 51991-294; 60429-063; 68094-123; 68462-137; 70518-1055; 0904-7264; 48087-0046; 48087-0158; 55512-0007; 0078-0337; 55154-2138; 60687-722; 63629-2075; 63629-4987; 0054-0199; 71205-411; 72888-087; 0781-6270; 48087-0118; 55512-0006; 42806-600; 50268-680; 51991-292; 62756-185; 70518-1980; 70518-2253; 71335-0144; 0904-7262; 55512-0016; 66039-905; 66406-0245; 17772-121; 51991-293; 55154-8198
UNII	VZI5B1W380
Synonyms	Oxcarbazepine \| 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide \| Trileptal \| Timox \| GP 47680

Chemical Information

Molecular Formula	C15H12N2O2
CAS Registry Number	28721-07-5
SMILES	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypophagia	14.03.01.006; 07.01.06.010; 19.09.01.004	0.000255%		Not Available
Autism spectrum disorder	19.22.02.002; 17.03.05.003	0.000426%		Not Available
Sudden unexplained death in epilepsy	17.12.03.019; 08.04.01.012	0.000341%		Not Available
Oral mucosal exfoliation	07.05.05.011	0.000170%		Not Available
Bone marrow failure	01.03.03.005	-	-
Suicidal behaviour	19.12.01.006	-	-	Not Available
Liver injury	12.01.17.012; 09.01.07.022	0.000341%		Not Available
Regurgitation	07.01.07.004	0.000170%		Not Available
Hyperammonaemic encephalopathy	17.13.01.005; 14.10.01.006	0.000341%		Not Available
Low birth weight baby	18.04.02.003	0.000341%		Not Available
Brain injury	19.07.03.007; 17.11.01.003	0.000255%		Not Available
Intellectual disability	19.21.06.001; 17.03.07.001	0.000255%		Not Available
Oropharyngeal pain	07.05.05.004; 22.12.03.016	0.000426%
Craniocerebral injury	17.11.01.007; 12.01.10.012	-	-	Not Available
Slow speech	19.19.02.004; 17.02.08.016	0.000375%		Not Available
Drug-induced liver injury	12.03.01.044; 09.01.07.023	0.000596%		Not Available
Drug reaction with eosinophilia and systemic symptoms	12.03.01.064; 23.03.05.005; 10.01.01.021	0.002895%		Not Available
Language disorder	19.19.01.006; 17.02.08.015	0.000170%		Not Available
Feeding intolerance	18.04.11.003; 14.02.01.006	0.000170%		Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.000341%
Coeliac disease	14.02.01.007; 10.04.04.012; 07.17.01.008	0.000426%		Not Available
Dermatitis exfoliative generalised	23.03.07.002; 10.01.01.029	0.000170%		Not Available
Epileptic aura	17.12.03.024	0.000170%		Not Available
Immunodeficiency common variable	10.03.01.006	0.000426%		Not Available
Infantile spasms	19.21.02.011; 17.12.03.027	0.000170%		Not Available
Neonatal respiratory distress syndrome	22.11.02.010; 18.04.10.003	0.000255%		Not Available
Normal newborn	18.08.06.001	0.000170%		Not Available
Oral lichen planus	23.03.08.012; 07.05.01.018	0.000170%		Not Available
Post-traumatic stress disorder	19.06.06.002	0.000170%		Not Available
Renal hypertension	20.01.08.005; 24.08.08.002	0.000170%		Not Available

The 16th Page First Pre 16 17 Next Last Total 17 Pages